Citadel Advisors’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$35.5M Sell
121,100
-116,200
-49% -$38.2M 0.01% 1692
2025
Q4
$83.2M Sell
237,300
-273,000
-53% -$92.3M 0.01% 987
2025
Q3
$165M Buy
510,300
+268,500
+111% +$83.5M 0.03% 567
2025
Q2
$94.1M Buy
241,800
+87,100
+56% +$35M 0.02% 808
2025
Q1
$67.3M Sell
154,700
-93,300
-38% -$37.5M 0.01% 932
2024
Q4
$91.5M Buy
248,000
+162,400
+190% +$68M 0.02% 783
2024
Q3
$44.5M Sell
85,600
-85,700
-50% -$45.8M 0.01% 1326
2024
Q2
$92.8M Hold
171,300
0.02% 730
2024
Q1
$88.8M Sell
171,300
-104,600
-38% -$52M 0.02% 778
2023
Q4
$130M Buy
275,900
+91,400
+50% +$42.3M 0.03% 541
2023
Q3
$80.3M Buy
184,500
+16,000
+9% +$7.26M 0.02% 754
2023
Q2
$74.9M Sell
168,500
-8,700
-5% -$4.01M 0.02% 787
2023
Q1
$81.5M Sell
177,200
-104,800
-37% -$49.9M 0.02% 736
2022
Q4
$145M Sell
282,000
-128,700
-31% -$65.3M 0.03% 475
2022
Q3
$187M Sell
410,700
-28,100
-6% -$13.4M 0.04% 328
2022
Q2
$212M Buy
438,800
+273,100
+165% +$135M 0.05% 263
2022
Q1
$81.4M Sell
165,700
-4,100
-2% -$1.87M 0.02% 769
2021
Q4
$78.7M Sell
169,800
-15,800
-9% -$6.65M 0.02% 827
2021
Q3
$69.2M Sell
185,600
-20,000
-10% -$7.6M 0.01% 892
2021
Q2
$78.5M Sell
205,600
-40,300
-16% -$15.4M 0.02% 813
2021
Q1
$88.3M Buy
245,900
+3,700
+2% +$1.19M 0.02% 650
2020
Q4
$77.8M Sell
242,200
-43,800
-15% -$13.4M 0.02% 684
2020
Q3
$76.8M Sell
286,000
-18,300
-6% -$4.92M 0.02% 604
2020
Q2
$80M Buy
304,300
+44,700
+17% +$11.9M 0.03% 515
2020
Q1
$58.9M Buy
259,600
+12,200
+5% +$3.32M 0.03% 568
2019
Q4
$74.7M Sell
247,400
-26,900
-10% -$7.4M 0.03% 542
2019
Q3
$65.9M Buy
274,300
+5,400
+2% +$1.48M 0.03% 599
2019
Q2
$75.9M Buy
268,900
+140,800
+110% +$38.5M 0.03% 512
2019
Q1
$36.8M Buy
128,100
+65,300
+104% +$18.9M 0.02% 871
2018
Q4
$16.5M Sell
62,800
-38,600
-38% -$10.6M 0.01% 1392
2018
Q3
$27.8M Buy
101,400
+32,100
+46% +$8.33M 0.01% 1134
2018
Q2
$16.5M Buy
69,300
+6,300
+10% +$1.46M 0.01% 1475
2018
Q1
$13.8M Sell
63,000
-10,100
-14% -$2.37M 0.01% 1435
2017
Q4
$16.4M Buy
73,100
+10,300
+16% +$2.19M 0.01% 1286
2017
Q3
$11.9M Buy
62,800
+30,000
+91% +$5.71M 0.01% 1449
2017
Q2
$6.17M Sell
32,800
-21,500
-40% -$3.86M 0.01% 1899
2017
Q1
$8.98M Sell
54,300
-10,300
-16% -$1.64M 0.01% 1520
2016
Q4
$9.29M Buy
64,600
+1,500
+2% +$201K 0.01% 1422
2016
Q3
$7.91M Buy
63,100
+14,600
+30% +$1.89M 0.01% 1573
2016
Q2
$6.37M Sell
48,500
-7,200
-13% -$985K 0.01% 1625
2016
Q1
$7.74M Buy
55,700
+3,700
+7% +$494K 0.01% 1393
2015
Q4
$7.25M Sell
52,000
-34,600
-40% -$4.77M 0.01% 1514
2015
Q3
$12.1M Sell
86,600
-11,200
-11% -$1.68M 0.01% 1217
2015
Q2
$16.1M Buy
97,800
+22,900
+31% +$3.66M 0.01% 1157
2015
Q1
$11.6M Sell
74,900
-39,500
-35% -$5.62M 0.01% 1337
2014
Q4
$14.4M Sell
114,400
-56,500
-33% -$6.98M 0.01% 1151
2014
Q3
$20.4M Buy
170,900
+17,900
+12% +$2.05M 0.02% 890
2014
Q2
$16.5M Sell
153,000
-20,300
-12% -$2.09M 0.02% 924
2014
Q1
$17.3M Sell
173,300
-3,000
-2% -$271K 0.02% 907
2013
Q4
$16.3M Buy
176,300
+57,000
+48% +$5.06M 0.02% 920
2013
Q3
$9.97M Buy
119,300
+29,100
+32% +$2.49M 0.02% 1104
2013
Q2
$7.38M Buy
+90,200
New +$6.75M 0.01% 1257

Other funds holding ELV

Citadel Advisors's ELV Position: Q1 2026 in Review

Citadel Advisors reduced its Elevance Health (ELV) stake by 6.3% in Q1 2026, selling an estimated $34.8M and leaving 1,562,219 shares worth $457M. The position accounts for 0.07% of the portfolio, ranked #199.

Citadel Advisors first reported a position in ELV in Q2 2013 and has held it in 49 quarters since. The position peaked at $585M in Q4 2025. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • Citadel Advisors held 1,562,219 shares of Elevance Health worth $457M as of Q1 2026.
  • Citadel Advisors sold 105,850 Elevance Health shares in Q1 2026, an estimated $34.8M.
  • Elevance Health made up 0.07% of Citadel Advisors's portfolio in Q1 2026, its #199 holding.
  • Citadel Advisors first reported a position in Elevance Health in Q2 2013 and has held it in 49 quarters since.
  • Citadel Advisors's Elevance Health position peaked at $585M in Q4 2025.
  • 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.